This webinar delves into three crucial topics related to imaging as a catalyst to predict responses to cancer immunotherapy. The featured speakers critically examine the evolving landscape of immunotherapy, the transformative power of predictive biomarkers and the emerging potential of artificial intelligence (AI) in enhancing the capabilities of radiomics, emphasizing the intricacies and latest breakthroughs in these areas.
Current State of Cancer Immunotherapy Theranostics:
Cancer immunotherapy theranostics are the predictive biomarkers of immunotherapy response. These critical indicators aid clinicians in identifying patients most likely to benefit from immunotherapy and those whose responses may be suboptimal. However, current tissue- or blood-based assays do not encompass all potential patient responses, and even when a beneficial outcome is predicted, a significant percentage of patients do not receive a clinical benefit from immunotherapy, underscoring the need for continued enhancement in predictive capabilities. Dr. Weiss will take attendees through the clinical outcomes and data related to clinically utilized biomarkers for cancer immunotherapy such PD-L1, TMB, MSI and MMR in selected cancer types, along with insights into Quibim’s experiences with cancer immunotherapy imaging classifiers.
Visualizing Patient Response with CD8+ T cells in Cancer:
Cytotoxic T cells expressing cell surface CD8 are the most powerful effectors in the anticancer immune response. Estimates from intra-tumoral CD8+ T cells from biopsied specimens have been found to correlate with outcomes in patients treated with immune checkpoint inhibitors across a range of solid tumors. However, biopsies are invasive, and these estimates do not reveal the whole picture due to the relatively small fraction of tumors in specimens. Evidence suggests CD8+ cells in lymph nodes or other lymphoid organs could play an important role in the tumor immunity cycle and response to immunotherapy. CD8+ cells can provide information that is not obtainable from tumor biopsy and may help better understand patient responses. In this webinar, Dr. Ferris will review the advantages of full body imaging of cancer patients focused on CD8+ cell status (CD8 ImmunoPET), particularly during cancer immunotherapy, revealing full-body CD8+ cell distributions in multiple lesions, lymph nodes and other lymphoid organs.
Radiomics and Artificial Intelligence:
Radiomics is a rapidly evolving field of research that aims to extract quantitative image features — the so-called radiomic features — from medical images. Radiomic features capture tissue and lesion characteristics such as heterogeneity and shape. When coupled with artificial intelligence (AI), a machine learning/deep learning algorithm can learn to adjust the importance of each feature or pattern and their interactions, to combine radiomic features into a predictive signature. Thus AI-derived clinical decision support algorithms can assist clinicians in distinguishing between the myriad of immune response patterns to achieve earlier and better identification of responders, non-responders and those likely to develop adverse events. Hear from featured speaker Ana Jimenez-Pastor, as they explore the integration of AI techniques in radiomics analysis for cancer immunotherapy response prediction.
Join this webinar to discover the present and transformative impact of predictive biomarkers on immunotherapy response, the role of cytotoxic T cells expressing CD8 in the anti-cancer immune response and the emerging field of radiomics and its potential merger with AI with a discussion on the promising opportunities this fusion presents for complex response assessments in immunotherapy.
Dr. Michael Ferris, PhD, Associate Director of Operations, ImaginAb Europe Ltd.
In his role, Dr. Michael Ferris assists ImaginAb’s clinical development programs, specializing in integrating CD8 ImmunoPET into partnered clinical studies, primarily focusing on oncology. Michael is also a member of the CD8 Consortium Steering Committee, a collaboration of four pharmaceutical companies committed to investigating and assessing the predictive and prognostic value of CD8+ cells in immunology-oncology. Michael brings over five years of experience in the clinical development of innovative PET imaging agents. He earned his MPhys in theoretical physics from the University of Reading and his PhD in mathematical physics from Lancaster University, UK.
Dr. Glen J. Weiss, MD, MBA, Chief Medical Officer (CMO), Quibim
Dr. Glen Weiss is an expert in clinical investigation, translational research and medical oncology, with a career spanning over 100 Phase 1-3 oncology studies and numerous biomarker/translational research studies. His academic pursuits began at Rutgers University, leading him to the Sackler School of Medicine at Tel Aviv University and to faculty positions at prestigious institutions, including Harvard Medical School and UMass Chan Medical School.
Previously serving as Vice President of Clinical Sciences and a medical lead for a company specializing in CAR-T therapies, Dr. Weiss also brings invaluable experience in biotech advisory roles, focusing on drug development strategy and clinical trial medical monitoring.
As Quibim’s CMO, Dr. Weiss provides strategic direction on personalized medicine, scientific development of platforms and clinical applications.
Ana Jimenez-Pastor, VP of Artificial Intelligence (AI), Quibim
Ana Jimenez-Pastor, holding degrees in telecommunications and biomedical engineering from the Polytechnic University of Valencia (Spain), currently serves as the VP of AI at Quibim. She leads the development of innovative AI solutions applied to medical imaging. With seven years of dedication to the research and clinical integration of solutions that combine image analysis, quantification and AI, Ana has contributed significantly to the field. Her involvement in coordinating various H2020 European projects on cancer study via AI and image analysis is noteworthy. She frequently presents her research as an author of over 10 publications and book chapters.
Who Should Attend?
This webinar will benefit life science decision makers in the following job roles/field:
- BioPharma VPs
- BioPharma CCO/COO
- Oncologist Specialist
- Chief Medical Officer
- Medical Director
- Clinical Director
- Clinical Project Manager
- Chief Global Operations
- Business Development
And hospital decision makers with the following job roles:
- Oncologist Specialist
- Chief Executive Officer
- Chief Financial Officer
- Chief Clinical Officer
What You Will Learn
Attendees will gain insights into:
- The basic principles of radiomics, its integration with AI for immunotherapy response prediction and its role in medical imaging
- Enhancing immunotherapy responses, leveraging CD8 ImmunoPET for clinical trials, its future in oncology decisions and interpreting ImmunoPET imaging
- Clinical outcomes and performance of assays related to key biomarkers (PD-L1, TMB, MSI, MMR) in select cancer types
At Quibim, we’re revolutionizing personalized medicine by delving beyond what the human eye can see. We employ AI-powered imaging tools derived from years of intensive research to assist doctors in diagnosis and anticipating patient progression. Our solutions transform imaging data into actionable predictions, enhancing patient outcomes and driving medical imaging innovation. Now internationally expanded, we’re excited to introduce our new line of products focused on predictive imaging biomarker panels, ensuring continuous advancement in life sciences and provider solutions.